Postoperative management of differentiated thyroid cancer.
暂无分享,去创建一个
[1] G. Manciet,et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma , 2005, European Journal of Nuclear Medicine.
[2] H. Biersack,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer , 1996, European Journal of Nuclear Medicine.
[3] F. Cetani,et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine , 1994, World Journal of Surgery.
[4] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] A. Oberg,et al. Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.
[6] S. Larson,et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.
[7] R. Kloos,et al. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? , 2002, The Journal of clinical endocrinology and metabolism.
[8] A. Pinchera,et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.
[9] W. Mendenhall,et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. , 2002, International journal of radiation oncology, biology, physics.
[10] G. Lindstedt,et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone , 2002, Journal of endocrinological investigation.
[11] J. Weissman,et al. MRI Detection of Cervical Metastasis From Differentiated Thyroid Carcinoma , 2001, The Laryngoscope.
[12] S. Larson,et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. , 2001, Thyroid : official journal of the American Thyroid Association.
[13] S. Krishnamurthy,et al. Ultrasound‐guided fine‐needle aspiration biopsy of the thyroid bed , 2001, Cancer.
[14] S. Larson,et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[15] L. Hann,et al. Advances in the detection of residual thyroid carcinoma. , 2001, Advances in internal medicine.
[16] R. Görges,et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. , 2000, Surgery.
[17] O. Hoekstra,et al. Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma. , 2000, The Netherlands journal of medicine.
[18] J. Llamas-Elvira,et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. , 2000, American journal of surgery.
[19] G. Coates,et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[21] A. King,et al. Staging papillary carcinoma of the thyroid: magnetic resonance imaging vs ultrasound of the neck. , 2000, Clinical radiology.
[22] E. Baudin,et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.
[23] P. V. van Rijk,et al. The detection of small carcinoma with 18F-FDG using a dual head coincidence camera. , 1999, European journal of radiology.
[24] O. Schober,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.
[25] B. Weintraub,et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.
[26] P. Ladenson,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Quantitative Reverse Transcription-Polymerase Chain Reaction of Circulating Thyroglobulin Messenger Ribonucleic Acid for Monitoring Patients wit , 2022 .
[27] R. Tambouret,et al. Ultrasound‐guided fine‐needle aspiration biopsy of the thyroid , 1999, Cancer.
[28] H. Biersack,et al. Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[29] Scott T. Grafton,et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. , 1999, Thyroid : official journal of the American Thyroid Association.
[30] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[31] D. Lee,et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] M. Ringel,et al. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. , 1999, Clinical chemistry.
[33] M. J. Pérez-Castejón,et al. La PET-FDG en el cáncer de tiroides ante niveles altos de tiroglobulina y rastreo 131I negativo. A propósito de un caso , 1999 .
[34] I. Fleming,et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.
[35] P. Ladenson,et al. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. , 1998, The Journal of clinical endocrinology and metabolism.
[36] Y. Menda,et al. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] P. Ladenson,et al. Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma , 1998, Annals of Internal Medicine.
[38] E. Baudin,et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.
[39] P. Chieng,et al. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports , 1998, Journal of endocrinological investigation.
[40] H. Jadvar,et al. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. , 1998, Nuclear medicine communications.
[41] P. Mikosch,et al. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] O. Schober,et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.
[43] M. Clausen,et al. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer , 1998, Langenbeck's Archives of Surgery.
[44] J. Rosai,et al. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Sone,et al. Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis. , 1998, AJNR. American journal of neuroradiology.
[46] R. Tsang,et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma , 1998, Cancer.
[47] P. Caron,et al. Immunoradiometric Assay of Thyroglobulin in Patients with Differentiated Thyroid Carcinomas: Need for Thyroglobulin Recovery Tests , 1998, Clinical chemistry and laboratory medicine.
[48] P. Ladenson,et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. , 1998, Thyroid : official journal of the American Thyroid Association.
[49] P. Parrilla,et al. High-resolution ultrasound associated with aspiration biopsy in the follow-up of patients with differentiated thyroid cancer , 1997, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[50] M. Dietlein,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.
[51] J. Garber,et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.
[52] T. Mccaffrey,et al. The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. , 1997, Archives of otolaryngology--head & neck surgery.
[53] C. Key,et al. Prognostic factors for thyroid carcinoma , 1997, Cancer.
[54] J. Chabot,et al. Detection of circulating thyroid cells in peripheral blood. , 1996, Surgery.
[55] J. Bringer,et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. , 1996, The Journal of clinical endocrinology and metabolism.
[56] J. Hanke,et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] C. Bal,et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.
[58] M. Schlumberger,et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] H. Sack,et al. Differentiated thyroid cancer: Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4) , 1996, Cancer.
[60] D. A. Meier,et al. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[61] J. Hanke,et al. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.
[62] S. Jhiang,et al. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.
[63] R. Tsang,et al. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. , 1994, The British journal of radiology.
[64] G. Németh,et al. Prophylactic external irradiation in differentiated thyroid cancer: a retrospective study over a 30-year observation period. , 1994, Oncology.
[65] H. Wanebo,et al. Recurrent Thyroid Cancer Role of Surgery Versus Radioactive Iodine (I131) , 1994, Annals of Surgery.
[66] P. Ladenson,et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.
[67] A. Avraham,et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[68] R. A’Hern,et al. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. , 1994, European journal of cancer.
[69] E. Bergstralh,et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.
[70] P. van Houtte,et al. Postoperative irradiation for thyroid cancer. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[71] E. Strong,et al. Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. , 1993, American journal of surgery.
[72] R. Wahl,et al. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. , 1993, The Journal of clinical endocrinology and metabolism.
[73] G. Masarotto,et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[74] H. Hoshi,et al. Detection of recurrent thyroid cancer: MR versus thallium-201 scintigraphy. , 1993, AJNR. American journal of neuroradiology.
[75] C. Reiners,et al. Surgical reintervention for differentiated thyroid cancer , 1993, The British journal of surgery.
[76] Steven J Brown,et al. The role of iodine‐131 and thallium‐201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma , 1993, Cancer.
[77] C. Begg,et al. Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.
[78] D. Johnston,et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.
[79] V S Hertzberg,et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] W. Simpson,et al. Management of local recurrence in well-differentiated thyroid carcinoma. , 1992, The Journal of surgical research.
[81] E. Bergstralh,et al. Papillary thyroid microcarcinoma : a study of 535 cases observed in a 50-year period: Discussion , 1992 .
[82] K. Johansen,et al. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[83] G. Ronga,et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[84] J. Chmiel,et al. Survival discriminants for differentiated thyroid cancer. , 1990, American journal of surgery.
[85] E. Kaplan,et al. Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.
[86] W. Sauerwein,et al. Survival rates in patients with differentiated thyroid carcinoma. Influence of postoperative external radiotherapy , 1990, Cancer.
[87] C. Marcocci,et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. , 1989, Surgery.
[88] B. Cady,et al. An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.
[89] I D Hay,et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? , 1988, Surgery.
[90] D. F. Preston,et al. Radioiodine therapy for differentiated thyroid carcinoma. , 1988, American journal of surgery.
[91] E. Bergstralh,et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.
[92] C. Higgins,et al. Recurrent thyroid carcinoma: characteristics on MR images. , 1988, Radiology.
[93] J. Charboneau,et al. US-guided biopsy of neck masses in postoperative management of patients with thyroid cancer. , 1988, Radiology.
[94] T. Panzarella,et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. , 1988, International journal of radiation oncology, biology, physics.
[95] B. Cady,et al. Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. , 1988, Archives of surgery.
[96] W. Taylor,et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. , 1987, Surgery.
[97] A. Pinchera,et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[98] S. McKinney,et al. Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. , 1987, The American journal of medicine.
[99] D. Kopans,et al. Sonography in the follow-up of 100 patients with thyroid carcinoma. , 1987, AJR. American journal of roentgenology.
[100] J. Ranstam,et al. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow‐up , 1986, Cancer.
[101] G. Braunstein,et al. Evaluation of Low-Dose Radioiodine Ablation Therapy in Postsurgical Thyroid Cancer Patients , 1985, Clinical nuclear medicine.
[102] A. Pinchera,et al. DIAGNOSTIC VALUE OF A SINGLE SERUM THYROGLOBULIN DETERMINATION ON AND OFF THYROID SUPPRESSIVE THERAPY IN THE FOLLOW‐UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER , 1985, Clinical endocrinology.
[103] M. Schlumberger,et al. External radiotherapy in thyroid cancers , 1985, Cancer.
[104] D. Berman,et al. Correlation of thyroglobulin measurements and radioiodine scans in the follow‐up of patients with differentiated thyroid cancer , 1985, Cancer.
[105] N. Ordóñez,et al. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. , 1985, The Journal of clinical endocrinology and metabolism.
[106] R. Lloyd,et al. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[107] D. Donohoe,et al. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow‐up of differentiated thyroid carcinoma , 1984, Cancer.
[108] V. R. McCready,et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. , 1984, The British journal of radiology.
[109] G. Guiraudon,et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment , 1984, Cancer.
[110] R. Gelman,et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. , 1983, Surgery.
[111] S. Refetoff,et al. The value of serum thyroglobulin measurement in clinical practice. , 1983, JAMA.
[112] V S Hertzberg,et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. , 1983, The New England journal of medicine.
[113] C. Gorman,et al. Thyroid remnant ablation: questionable pursuit of an ill-defined goal. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[114] L. Degroot,et al. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. , 1982, Annals of internal medicine.
[115] M. Ashcraft,et al. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. , 1981, The American journal of medicine.
[116] E. Mazzaferri,et al. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. , 1981, The American journal of medicine.
[117] N. Samaan,et al. 131I therapy in differentiated thyroid carcinoma: M. D. Anderson hospital experience , 1981 .
[118] B. Cady,et al. Changing Clinical, Pathologic, Therapeutic, and Survival Patterns in Differentiated Thyroid Carcinoma , 1976, Annals of surgery.
[119] R. Adler,et al. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. , 1976, The American journal of medicine.
[120] J. Shah,et al. Papillary carcinoma of the thyroid , 1963 .